Insider Ledger
PBYI insider buying and SEC filings, explained
Puma Biotechnology, Inc. · CIK 1401667
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
- Former names
- INNOVATIVE ACQUISITIONS CORP
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$97K
Planned sales (10b5-1)
$2.0M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 14, 2026 | Planned (10b5-1) | Troy Edward Wilson (Director) sold 5,000 shares at $9.10 ($46K), marked as a 10b5-1 plan trade. Holdings down 8% to 54,750 shares. | SEC filing Filed Sep 16, 2026 |
| Sep 14, 2026 | Planned (10b5-1) | Alessandra Cesano (Director) sold 62,150 shares at about $9.12 ($567K), marked as a 10b5-1 plan trade. Holdings down 52% to 56,700 shares. | SEC filing Filed Sep 16, 2026 |
| Jul 6, 2026 | Planned (10b5-1) | Alan H. Auerbach (CEO and Director) sold 44,058 shares at $8.26 ($364K), marked as a 10b5-1 plan trade. Holdings down 1% to 7,261,671 shares. | SEC filing Filed Jul 8, 2026 |
| Jul 6, 2026 | Planned (10b5-1) | Douglas M. Hunt (Officer) sold 8,460 shares at $8.26 ($70K), marked as a 10b5-1 plan trade. Holdings down 4% to 196,841 shares. | SEC filing Filed Jul 8, 2026 |
| Jul 6, 2026 | Planned (10b5-1) | Maximo F. Nougues (CFO) sold 9,386 shares at $8.26 ($78K), marked as a 10b5-1 plan trade. Holdings down 4% to 230,637 shares. | SEC filing Filed Jul 8, 2026 |
| Jun 12, 2026 | Planned (10b5-1) | Troy Edward Wilson (Director) sold 10,800 shares at about $7.20 ($78K), marked as a 10b5-1 plan trade. Holdings down 15% to 59,750 shares. | SEC filing Filed Jun 15, 2026 |
| Jun 12, 2026 | Planned (10b5-1) | Brian M Stuglik (Director) sold 8,100 shares at about $7.20 ($58K), marked as a 10b5-1 plan trade. Holdings down 7% to 113,858 shares. | SEC filing Filed Jun 15, 2026 |
| Jun 12, 2026 | Planned (10b5-1) | Adrian Senderowicz (Director) sold 27,000 shares at about $7.20 ($194K), marked as a 10b5-1 plan trade. Holdings down 50% to 27,000 shares. | SEC filing Filed Jun 15, 2026 |
| Jun 12, 2026 | Planned (10b5-1) | Jay M. Moyes (Director) sold 22,000 shares at about $7.22 ($159K), marked as a 10b5-1 plan trade. Holdings down 27% to 58,322 shares. | SEC filing Filed Jun 15, 2026 |
| Jun 12, 2026 | Planned (10b5-1) | Allison Dorval (Director) sold 11,610 shares at about $7.20 ($84K), marked as a 10b5-1 plan trade. Holdings down 11% to 90,780 shares. | SEC filing Filed Jun 15, 2026 |
| Jan 6–7, 2026 | Planned (10b5-1) | Alan H. Auerbach (CEO and Director) sold 34,950 shares between Jan 6 and Jan 7 at about $5.86 ($205K), marked as a 10b5-1 plan trade. Holdings down <1% to 7,145,951 shares. | SEC filing Filed Jan 8, 2026 |
| Jan 6–7, 2026 | Planned (10b5-1) | Douglas M. Hunt (Officer) sold 8,987 shares between Jan 6 and Jan 7 at about $5.86 ($53K), marked as a 10b5-1 plan trade. Holdings down 5% to 155,907 shares. | SEC filing Filed Jan 8, 2026 |
| Jan 6–7, 2026 | Planned (10b5-1) | Maximo F. Nougues (CFO) sold 10,945 shares between Jan 6 and Jan 7 at about $5.86 ($64K), marked as a 10b5-1 plan trade. Holdings down 5% to 193,284 shares. | SEC filing Filed Jan 8, 2026 |
| Nov 11, 2025 | Sale | Michael Patrick Miller (Director) sold 20,000 shares at about $4.86 ($97K). Holdings down 27% to 54,000 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 13, 2025 |
11 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow PBYI in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.